All In Biotech

Drug Trial Radar · NCT04999969

Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours

A Phase II Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumours

Last checked: Nov 19, 2026Latest source record: Aug 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registry

Status

Active, not recruiting

Enrollment

126

Actual

Start

Dec 10, 2021

Primary completion

Oct 7, 2024

Study completion Nov 30, 2026

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Aug 11, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The proposed study is designed to examine the effects of AZD0171 and durvalumab in combination with standard-of-care chemotherapy in patients with pancreatic ductal adenocarcinoma (PDAC).

Conditions

  • Locally Advanced or Metastatic Solid Tumours

Interventions

  • AZD0171Drug

    AZD0171

  • DurvalumabDrug

    Durvalumab

  • GemcitabineDrug

    Chemotherapy (Standard-of-Care)

  • Nab-paclitaxelDrug

    Chemotherapy (Standard-of-Care)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse Events (AEs), Immune Mediated AEs (imAEs) and Serious AEs (SAEs)Time frame: From Cycle 1 Day 1 (each cycle was 28 days in length) until Day 90 (post last dose of study intervention), up to 34 months
  2. Overall Survival at 12 Months (OS-12)Time frame: At 12 months

Locations

34 sites in 4 countries. Site status is shown where the registry gives one.

  • Research Site

    La Jolla, California

  • Research Site

    Los Angeles, California

  • Research Site

    Orange, California

  • Research Site

    Ventura, California

  • Research Site

    Atlanta, Georgia

  • Research Site

    Coeur d'Alene, Idaho

  • Research Site

    Boston, Massachusetts

  • Research Site

    Ann Arbor, Michigan

  • Research Site

    Grand Rapids, Michigan

  • Research Site

    Buffalo, New York

  • Research Site

    New York, New York

  • Research Site

    Portland, Oregon

  • Research Site

    San Antonio, Texas

  • Research Site

    Charlottesville, Virginia

  • Research Site

    Seattle, Washington

  • Research Site

    Madison, Wisconsin

  • Research Site

    Barrie, Ontario, Canada

  • Research Site

    Toronto, Ontario, Canada

  • Research Site

    Toronto, Ontario, Canada

  • Research Site

    Seongnam-si, South Korea

  • Research Site

    Seongnam-si, South Korea

  • Research Site

    Seoul, South Korea

  • Research Site

    Seoul, South Korea

  • Research Site

    Seoul, South Korea

  • Research Site

    Seoul, South Korea

  • Research Site

    Seoul, South Korea

  • Research Site

    Badalona, Spain

  • Research Site

    Barcelona, Spain

  • Research Site

    Madrid, Spain

  • Research Site

    Madrid, Spain

  • Research Site

    Madrid, Spain

  • Research Site

    Madrid, Spain

  • Research Site

    Majadahonda, Spain

  • Research Site

    Pamplona, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.